All In Biotech

Drug Trial Radar · NCT07798193

A Study of SYH2085 Tablets Compared With Placebo in Chinese Adult Patients With Uncomplicated Influenza.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Preliminarily Evaluate the Efficacy and Safety of SYH2085 Tablets in Chinese Adult Participants With Uncomplicated Influenza

Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 213 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

213

Planned (sponsor's estimate)

Start

Oct 10, 2026

Primary completion

Apr 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of SYH2085 tablets compared with placebo in Chinese adult participants with uncomplicated influenza. The study plans to enroll patients with typical systemic and respiratory influenza symptoms, with symptom onset ≤48 hours.

Conditions

  • Influenza

Interventions

  • SYH2085Drug

    One or two 40-mg SYH2085 tablets taken orally

  • PlaceboDrug

    One or two placebo tablets taken orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to resolution of all influenza symptoms (hours)Time frame: Up to Day22

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.